Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

In the Spotlight

Glycolysis Back in the Limelight: Systemic Targeting of HK2 Blocks Tumor Growth

Susana Ros and Almut Schulze
Susana Ros
Gene Expression Analysis Laboratory, Cancer Research UK London Research Institute, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Almut Schulze
Gene Expression Analysis Laboratory, Cancer Research UK London Research Institute, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2159-8290.CD-13-0565 Published October 2013
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Summary: In a recent issue of Cancer Cell, Patra and colleagues report findings that underscore the importance of Hexokinase 2 (HK2) in tumor initiation and maintenance. The authors also show that HK2 can be systemically deleted without adverse physiologic consequences. These findings provide attractive insights into HK2 deletion as a potential therapeutic intervention for cancer. Cancer Discov; 3(10); 1105–7. ©2013 AACR.

A key hallmark of cancer cells is their capacity to metabolize glucose at an elevated rate (1, 2). Critical to this highly glycolytic phenotype is the first enzymatic step of glycolysis, catalyzed by hexokinase (HK), during which glucose is phosphorylated and thereby trapped within the cell. There are four HK enzymes in mammals, HK1, HK2, HK3, and glucokinase (GCK), which are structurally similar but expressed in a tissue- specific manner (3). Remarkably, only HK2 is overexpressed in cancer cells (4) and contributes to the high glycolytic rate in tumors (5). Given the selective expression of HK2 in cancer, Patra and colleagues (6) investigated whether targeting this particular glycolytic enzyme could be used for cancer therapy.

Several previous studies have reported that inhibition of HK2 can block cancer cell survival. Depletion of HK2 with short hairpin RNA (shRNA) inhibited tumor growth in a xenograft model of glioblastoma multiforme (7). Moreover, HK2 mRNA and protein levels were found to be upregulated in a derivative of the human breast carcinoma cell line MDA-MB-231 that metastasizes to the brain (8). HK2 knockdown using shRNA reduced cell proliferation and viability under conditions of limited glucose availability in these cells (8). The micro-RNA miR-143, which is downregulated in response to activation of the mTOR, has been shown to reduce glucose metabolism and inhibit lung cancer cell proliferation and tumor formation by targeting HK2, an effect that was reproduced by direct silencing of HK2 (9). However, the role of HK2 in tumor initiation and maintenance remained unclear. More importantly, it had to be shown that systemic inhibition of HK2 could be a viable approach to treating cancer.

Patra and colleagues (6) examined the role of HK2 in tumor initiation using a genetic model of non–small cell lung carcinoma (NSCLC) induced by expression of activated KRas (KRAS-LA2) and a model of breast cancer induced by expression of activated ERBB2/Neu (MMTV-neu). They found that genetic deletion of Hk2 reduced overall tumor burden in lungs of Kras-mutant mice. This was caused by a reduction in the number rather than the size of individual lesions, indicating a role for HK2 in tumor initiation. In the breast cancer model, genetic deletion of Hk2 extended the latency of tumor development, resulting in a substantial increase in survival. The study also addressed whether HK2 is also required for tumor maintenance in lung cancer. HK2 ablation, via inducible shRNA, reduced the growth of NSCLC cells in a xenograft model. Similar inhibition of proliferation was also observed in cancer cells derived from a genetic model of KRAS-driven lung cancer (KRAS-LA2) after genetic deletion of Hk2. The authors also show that deletion of Hk2 in murine cancer cells derived from the MMTV-neu mouse model reduces their ability to form tumors after orthotopic implantation into athymic mice, again associated with reduced rates of proliferation. These results show a role for HK2 in tumor initiation and maintenance. However, it could also be interesting to address whether HK2 also plays a role in the progression to the metastatic state. Indeed, increased HK2 expression has been associated with poor patient survival in a cohort of 123 resected brain metastases of breast cancer (8).

Patra and colleagues (6) addressed the metabolic consequences of Hk2 deletion in cancer cell lines derived from the KRAS-LA2 model. They found that Hk2 deletion caused a reduction in the entry of metabolites into the serine biosynthesis pathway, reduced glucose- and glutamine-dependent fatty acid biosynthesis, and impaired nucleotide biosynthesis through the nonoxidative arm of the pentose phosphate pathway. They also found that Hk2 deletion inhibited the entry of glutamine-derived metabolites into the tricarboxylic acid cycle (anaplerosis) but increased glutamine-derived production of citrate by reductive carboxylation of α-ketoglutarate, thereby partially compensating for the reduction in glucose-derived citrate and acetyl-CoA for lipid synthesis (Fig. 1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Remodeling of cancer metabolism by HK2. Schematic illustration of the proposed metabolic consequences induced by HK2 in cancer cells. Increased expression of HK2 in cancer cells drives nucleotide and lipid biosynthesis as well as glutamine-dependent anaplerosis. This supports anabolic metabolism, which is essential for tumor growth. Increased flux is depicted in red, decreased in green. TCA, tricarboxylic acid; GLUT, glucose transporter.

These results identify HK2 as a key player in the diversion of glucose-derived carbons into pathways required for anabolic processes in cancer cells and could explain why cancer cells express such high levels of this enzyme. But why do cancer cells preferentially use HK2 instead of other hexokinases? HK2 has high affinity for glucose and harbors two catalytic domains that have both retained their catalytic activity. In addition, HK2 has an N-terminal domain that allows it to bind to the mitochondrial outer membrane voltage-dependent anion channel (VDAC). Binding to VDAC enhances the affinity of hexokinases for ATP and makes them insensitive to inhibition by their product, glucose-6-phosphate (3). Mitochondrial HK2 also inhibits apoptosis by preventing the recruitment of proapoptotic proteins such as Bax (10), by regulating the mitochondrial permeability transition pore (11), and by limiting the production of reactive oxygen species (ROS; ref. 12). More recently, it has been shown that the Tp53-induced glycolysis and apoptosis regulator binds to and activates mitochondrial HK2 in hypoxic cells, which resulted in reduced levels of ROS and lowered cell death (13).

Mitochondrial association of HK2 couples glucose phosphorylation to oxidative metabolism and the control of apoptosis (14). It has previously been shown that HK2 binding to VDAC is promoted by activation of oncogenic signaling pathways, such as phosphoinositide 3-kinase (PI3K)/AKT activation (15). Interestingly, Patra and colleagues (6) now show that oncogenic Ras also increases the expression of HK2, and that both PI3K and MAP–ERK kinase (MAPK) signaling contribute to this induction, thereby adding an additional mode of regulation of metabolic activity in cancer cells.

Another important point addressed by Patra and colleagues (6) is whether systemic inhibition of HK2 is effective in blocking tumor growth without producing any adverse physiologic consequences. HK2 is expressed mostly in embryonic tissues and in adult adipose tissue as well as skeletal and cardiac muscle (3). To investigate the effect of systemic deletion, the authors deleted Hk2 in the KRAS-LA2 model by using an inducible CRE recombinase at 2 months of age, when tumor initiation is likely to have already occurred. This late deletion of Hk2 resulted in a reduction of tumor burden, with some of the residual lesions showing normal levels of Hk2 expression, most likely due to incomplete excision. These observations suggest that systemic ablation of HK2 may be a way of selectively killing cancer cells without toxicity to healthy tissues.

The results shown by Patra and colleagues (6) provide evidence for the potential effectiveness of HK2-specific inhibitors. Current agents targeting HK2, like 3-bromopyruvate and 2-deoxyglucose, may have limited clinical potential due to low specificity. One possible strategy to improve selectivity would be to target HK2 binding to VDAC, thereby blocking its mitochondrial association and reducing its activity. In this context, it will be interesting to investigate whether inhibition of mitochondrial association will replicate the metabolic consequences of HK2 ablation observed in the current study. Selective inhibitors of HK2 could be used to treat specific patient populations, such as those showing mutations in oncogenic pathways that promote HK2 expression and activity. In addition, 18F-Fludeoxyglucose-positron emission tomography could also be used for patient stratification. Finally, inhibition of HK2 could also be attractive for use in combination with chemotherapeutic drugs or targeted therapies.

In summary, Patra and colleagues (6) provide important insights into the role of HK2 in tumor initiation and maintenance as well as the metabolic consequences of HK2 depletion. While the feasibility of the systemic targeting of glycolytic enzymes for cancer therapy is not fully established, HK2 could be an attractive candidate for such intervention.

Disclosure of Potential Conflicts of Interest

A. Schulze performs minor consultancy work for TPP Global Development. No potential conflicts of interest were disclosed by the other author.

  • ©2013 American Association for Cancer Research.

References

  1. 1.↵
    1. Gatenby RA,
    2. Gillies RJ
    . Why do cancers have high aerobic glycolysis?Nat Rev Cancer 2004;4:891–9.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Vander Heiden MG,
    2. Cantley LC,
    3. Thompson CB
    . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029–33.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Wilson JE
    . Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 2003;206:2049–57.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Shinohara Y,
    2. Yamamoto K,
    3. Kogure K,
    4. Ichihara J,
    5. Terada H
    . Steady state transcript levels of the type II hexokinase and type 1 glucose transporter in human tumor cell lines. Cancer Lett 1994;82:27–32.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Mathupala SP,
    2. Ko YH,
    3. Pedersen PL
    . Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006;25:4777–86.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Patra KC,
    2. Wang Q,
    3. Bhaskar PT,
    4. Miller L,
    5. Wang Z,
    6. Wheaton W,
    7. et al.
    Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 2013;24:213–28.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Wolf A,
    2. Agnihotri S,
    3. Micallef J,
    4. Mukherjee J,
    5. Sabha N,
    6. Cairns R,
    7. et al.
    Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 2011;208:313–26.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Palmieri D,
    2. Fitzgerald D,
    3. Shreeve SM,
    4. Hua E,
    5. Bronder JL,
    6. Weil RJ,
    7. et al.
    Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res 2009;7:1438–45.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Fang R,
    2. Xiao T,
    3. Fang Z,
    4. Sun Y,
    5. Li F,
    6. Gao Y,
    7. et al.
    MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J Biol Chem 2012;287:23227–35.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Pastorino JG,
    2. Shulga N,
    3. Hoek JB
    . Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem 2002;277:7610–8.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Chiara F,
    2. Castellaro D,
    3. Marin O,
    4. Petronilli V,
    5. Brusilow WS,
    6. Juhaszova M,
    7. et al.
    Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PloS One 2008;3:e1852.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. da-Silva WS,
    2. Gomez-Puyou A,
    3. de Gomez-Puyou MT,
    4. Moreno-Sanchez R,
    5. De Felice FG,
    6. de Meis L,
    7. et al.
    Mitochondrial bound hexokinase activity as a preventive antioxidant defense: steady-state ADP formation as a regulatory mechanism of membrane potential and reactive oxygen species generation in mitochondria. J Biol Chem 2004;279:39846–55.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Cheung EC,
    2. Ludwig RL,
    3. Vousden KH
    . Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death. Proc Natl Acad Sci U S A 2012;109:20491–6.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Robey RB,
    2. Hay N
    . Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 2006;25:4683–96.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Majewski N,
    2. Nogueira V,
    3. Bhaskar P,
    4. Coy PE,
    5. Skeen JE,
    6. Gottlob K,
    7. et al.
    Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 2004;16:819–30.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Cancer Discovery: 3 (10)
October 2013
Volume 3, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Glycolysis Back in the Limelight: Systemic Targeting of HK2 Blocks Tumor Growth
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Glycolysis Back in the Limelight: Systemic Targeting of HK2 Blocks Tumor Growth
Susana Ros and Almut Schulze
Cancer Discov October 1 2013 (3) (10) 1105-1107; DOI: 10.1158/2159-8290.CD-13-0565

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Glycolysis Back in the Limelight: Systemic Targeting of HK2 Blocks Tumor Growth
Susana Ros and Almut Schulze
Cancer Discov October 1 2013 (3) (10) 1105-1107; DOI: 10.1158/2159-8290.CD-13-0565
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Disclosure of Potential Conflicts of Interest
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • ATR Inhibition as an Attractive Therapeutic Resource against Cancer
  • Conditional Cancer Immunotherapy as a Safer Way to Step on the Gas
  • Suppressing Nucleotide Exchange to Inhibit KRAS-Mutant Tumors
Show more In the Spotlight
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement